ROS

The transmembrane proto-oncogene receptor tyrosine kinase (RTK) ROS is one of the last two remaining orphan receptor tyrosine kinases. Its normal expression pattern is tightly spatiotemporally restricted during development. The ectopic expression, as well as the production of variable mutant forms of ROS kinase, has been reported in a number of cancers, such as glioblastoma multiforme, and non-small cell lung cancer, suggesting a role for ROS kinase in deriving such tumors. It is thought also that the c-ROS gene may have a role in some cardiovascular diseases, and the fact that homozygous male mice targeted against the c-ROS gene are healthy but infertile has inspired researchers to think about ROS inhibition as a method for the development of new male contraceptives.

ROS1 is a transmembrane receptor tyrosine kinase proto-oncogene that has been shown to have rearrangements with several genes in glioblastoma, non-small-cell lung cancer (NSCLC), and other neoplasms, including intrachromosomal fusion with GOPC due to microdeletions at 6q22.1. ROS1 fusion events are important findings in these tumors, as they are potentially targetable alterations with newer tyrosine kinase inhibitors.

ALK/ROS1-IN-1

Cat. No.: HY-130794

ALK/ROS1-IN-1 (compound 2e) is a potent and selective anti crizotinib-resistant **ALK/ROS1** dual inhibitor, with IC_{50}s of 0.174 μM and 0.530 μM for ALK and ROS1 enzyme, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antibacterial agent 69

Cat. No.: HY-144252

Antimicrobial agent 69 is a novel structural antimicrobial regulator and has been used to fight deadly multidrug-resistant bacterial infections, and its < b > MICs < / b > value is 2.978 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antibacterial agent 70

Cat. No.: HY-144255

Antibacterial agent 70 is a new dihydropyrimidinone imidazole hybrid antibacterial agent, and its < b > MIC < / b > value is 0.5 μg/mL.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anticancer agent 15

Cat. No.: HY-139860

Anticancer agent 15 is capable of significantly increasing the cellular level of **ROS** and inducing melanoma cancer cell death via necroptosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anticancer agent 42

Cat. No.: HY-146516

Anticancer agent 42 (compound 10d) is an orally active anticancer agent, and shows a potent antitumor activity against MDA-MB-231 cell with an IC_{50} of 0.07 μM. Anticancer agent 42 can exert its anticancer activity by activating apoptotic pathway and **p53** expression.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antitumor agent-55

Cat. No.: HY-146038

Antitumor agent-55 (compound 5q) is a potent antitumor agent. Antitumor agent-55 effectively inhibits PC3, with an IC_{50} of 0.91 μM. Antitumor agent-55 effectively inhibits the colony formation, suppresses the cell migration in PC3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apogossypolone

(ApoG2)

Cat. No.: HY-19551

Apogossypolone (ApoG2) is an orally active **Bcl-2 family proteins** inhibitor with K_i values of 35, 25 and 660 nM for Bcl-2, Mcl-1 and Bcl-X_L, respectively. Apogossypolone shows antitumor activities, induces cell **apoptosis** and **autophagy**. Apogossypolone also has antifungal activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Capillarisin

Cat. No.: HY-121192

Capillarisin, as a constituent from Artemisiae Capillaris herba, is found to exert anti-inflammatory and antioxidant properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Capsanthin

Cat. No.: HY-125711

Capsanthin is a carotenoid that has been found in C. annuum. Capsanthin has antioxidantantitumor and anti-inflammatory effects.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chol-CTPP

Cat. No.: HY-144825

Chol-CTPP is a ligand with dual targeting effect on blood-brain barrier (BBB) and **glioma** cells. Lip-CTPP can be gained by Chol-CTPP and another mitochondria targeting ligand (Chol-TPP).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Cinnamtannin B-1

Cat. No.: HY-130237

Cinnamtannin B-1 is a proanthocyanidin with multiple biological functions, including antioxidant effects. Cinnamtannin B-1 inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced osteoporosis in vivo.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Crizotinib

(PF-02341066) Cat. No.: HY-50878

Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive **ALK** and **c-Met** inhibitor with IC_{50}s of 20 and 8 nM, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Crizotinib hydrochloride

(PF-02341066 hydrochloride) Cat. No.: HY-50878A

Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual **ALK** and **c-Met** inhibitor with IC_{50}s of 20 and 8 nM, respectively.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Crizotinib-d5

(PF-02341066-d5) Cat. No.: HY-50878S

Crizotinib-d5 (PF-02341066-d5) is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive **ALK** and **c-Met** inhibitor with IC_{50}s of 20 and 8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Derrone

Cat. No.: HY-N3737

Derrone, a prenylated isoflavones, is an **Aurora kinase** inhibitor, with IC_{50} values of 6 and 22.3 μM against **Aurora B** and **Aurora A**, respectively. Derrone shows anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Entrectinib

(NMS-E628; RXDX-101) Cat. No.: HY-12678

Entrectinib (NMS-E628) is a potent, orally available, and CNS-active **pan-Trk**, **ROS1**, and **ALK** inhibitor. Entrectinib inhibits TrkA, TrkB, TrkC, ROS1 and ALK with IC_{50} values of 1, 3, 5, 12 and 7 nM, respectively. Antitumor activity.



Purity: 99.32%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

F-1

Cat. No.: HY-112801

F-1 is a potent **ALK** and **ROS1** dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC_{50}s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALK^{WT}, $ROS1^{WT}$, ALK^{L1196M} and ALK^{G1202R}, respectively.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fascaplysin

Cat. No.: HY-112328

Fascaplysin is an antimicrobial and cytotoxic red pigment, that can come from the marine sponge (Fascaplysinopsis sp.). Fascaplysin has been synthesized in seven steps from indole (65% yield).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GGTI-2154

Cat. No.: HY-16229

GGTI-2154 is a potent and selective inhibitor of **geranylgeranyltransferase I (GGTase I)**, with an IC_{50} of 21 nM. GGTI-2154 shows more than 200-fold selectivity for GGTase I over FTase (IC50=5600 nM). GGTI-2154 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GGTI-2154 hydrochloride

Cat. No.: HY-16229A

GGTI-2154 hydrochloride is a potent and selective inhibitor **geranylgeranyltransferase I (GGTase I)**, with an IC_{50} of 21 nM. GGTI-2154 hydrochloride shows more than 200-fold selectivity for GGTase I over FTase (IC50=5600 nM). GGTI-2154 hydrochloride can be used for the research of cancer.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GGTI-2418

Cat. No.: HY-16231

GGTI-2418 is a highly potent, competitive, and selective **geranylgeranyltransferase I** (**GGTase I**) inhibitor. GGTI-2418 inhibits **GGTase I** and FTase activities with IC_{50}s of 9.5 nM and 53 μM, respectively.



Purity: 98.04%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Iruplinalkib

(WX-0593)

Cat. No.: HY-145574

Iruplinalkib (WX-0593) is a potent, selective, and orally active inhibitor of **ALK** and **ROS1** tyrosine kinase. Iruplinalkib (WX-0593) shows favorable safety and promising antitumor activity in advanced NSCLC with ALK or ROS1 rearrangement.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lorlatinib

(PF-06463922)

Cat. No.: HY-12215

Lorlatinib (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive **ROS1/ALK** inhibitor. Lorlatinib has K_is of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALK^{L1196M}, respectively. Lorlatinib has anticancer activity.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lorlatinib-13C,d3

(PF-06463922-13C,d3)

Cat. No.: HY-12215S

Lorlatinib-13C,d3 (PF-06463922-13C,d3) is the 13C- and deuterium labeled Lorlatinib. Lorlatinib (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive **ROS1/ALK** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Malvidin-3-galactoside chloride

Cat. No.: HY-N6623

Malvidin-3-galactoside chloride, an anthocyanin monomer, induces hepatocellular carcinoma (HCC) cells cycle arrest and **apoptosis**. Malvidin-3-galactoside chloride inhibits the production and accumulation of **ROS**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MAO-B-IN-7

Cat. No.: HY-146762

MAO-B-IN-7 is a potent and blood-brain barrier permeable **MAO-B** and **AChE** inhibitor with IC_{50}s of 41 nM, 87 nM and 0.3 μM for human AChE, electric eel AChE and MAO-B, respectively. MAO-B-IN-7 can effectively alleviate oxidative stress and neuroinflammatory damage.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Merestinib

(LY2801653)

Cat. No.: HY-15514

Merestinib (LY2801653) is a potent, orally bioavailable **c-Met** inhibitor (K_i=2 nM) with anti-tumor activities.



Purity: 99.99%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Merestinib dihydrochloride

(LY2801653 dihydrochloride)

Cat. No.: HY-15514A

Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable **c-Met** inhibitor (K_i=2 nM) with anti-tumor activities.



Purity: 99.36%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MitoPQ

(MitoParaquat)

Cat. No.: HY-130278

MitoPQ is a **mitochondria**-targeted redox cycler. MitoPQ produces superoxide by redox cycling at the flavin site of complex I, selectively increasing superoxide production within mitochondria. MitoPQ can be used in antioxidant study.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nrf2-ARE/hMAO-B/QR2 modulator 1

Cat. No.: HY-144635

Nrf2-ARE/hMAO-B/QR2 modulator 1 is a Resveratrol-based multitarget-directed ligands with IC_{50}s of 8.05, 9.83 and 0.57 μM for **hMAO-B**, **NRF2** and **QR2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nrf2/HO-1-IN-1

Cat. No.: HY-146971

Nrf2/HO-1-IN-1 is a potent **Nrf2/HO-1** pathway inhibitor, with an IC_{50} value of 0.38 μM for **NO**. Nrf2/HO-1-IN-1 can significantly reduce the level of **ROS** in cells. Nrf2/HO-1-IN-1 can be used for researching anti-inflammatory.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Orniplabin

(SMTP-7)

Cat. No.: HY-122311

Orniplabin (SMTP-7) is a low-molecular-weight compound that enhances plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

p38 MAPK-IN-3

Cat. No.: HY-144697

p38 MAPK-IN-3 (Compound 2c) is a **p38α MAPK** inhibitor. p38 MAPK-IN-3 has antitumor activities and induces **apoptosis** and **ROS**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Phyltetralin

Cat. No.: HY-121397

Phyltetralin (Compound 10) is a natural product than can be isolated from the hexane-ethyl acetate extract of Phyllanthus amarus leaves. Phyltetralin possesses immunosuppressive effects on different lineages of innate immune system.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Repotrectinib

(TPX-0005)

Cat. No.: HY-103022

Repotrectinib (TPX-0005) is a potent **ROS1** (IC_{50}=0.07 nM) and **TRK** (IC_{50}=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib potently inhibits WT **ALK** (IC_{50}=1.01 nM). Repotrectinib has anti-cancer activity.



Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Taletrectinib

(DS-6051b; AB-106)

Cat. No.: HY-131003

Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective **ROS1/NTRK** inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC_{50}s of 0.207, 0.622, 2.28, and 0.98 nM, respectively.



Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Taletrectinib free base

(DS-6051b free base; AB-106 free base)

Cat. No.: HY-131003A

Taletrectinib (DS-6051b) free base is a potent, orally active, and next-generation selective **ROS1/NTRK** inhibitor. Taletrectinib free base potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC_{50}s of 0.207, 0.622, 2.28, and 0.98 nM, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Topo I-IN-1

Cat. No.: HY-145859

Topo I-IN-1 (Compound 14d) is a potent **Topo I** inhibitor with antitumor activity and DNA intercalative capability. Topo I-IN-1 induces cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Topoisomerase I/II inhibitor 3

Cat. No.: HY-146504

Topoisomerase I/II inhibitor 3 (compound 7) is a potent **topoisomerase I (Topo I)** and **II (Topo II)** dual inhibitor. Topoisomerase I/II inhibitor 3 can inhibit cell proliferation, invasion and migration, and induce **apoptosis** by inhibiting **PI3K**/Akt/mTOR signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tubulin polymerization-IN-6

Cat. No.: HY-146505

Tubulin polymerization-IN-6 (compound 5f) is a potent **tubulin polymerization** inhibitor, with an IC_{50} of 1.09 μM. Tubulin polymerization-IN-6 inhibits cell migration and tube formation and contributes to the anti-angiogenesis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VEGFR-2-IN-19

Cat. No.: HY-146367

VEGFR-2-IN-19 (Compound 15b) is a potent **VEGFR2** inhibitor. VEGFR-2-IN-19 induces cell **apoptosis** and increases intracellular **reactive oxygen species** level. VEGFR-2-IN-19 can be used as an anticancer agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WY-135

Cat. No.: HY-111416

WY-135 is an **ALK** (IC_{50}=1.4 nM) and **ROS1** (IC_{50}=1.1 nM) dual inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-Carotene

(Provitamin A; beta-Carotene)

Cat. No.: HY-N0411

β-Carotene (Provitamin A), a carotenoid compound, is a naturally-occurring vitamin A precursor. β-Carotene is a modulator of **reactive oxygen species (ROS)**, with antioxidant and antiinflammatory activities.



Purity: ≥98.0%
Clinical Data: Launched
Size: 50 mg, 100 mg

β-Nor-lapachone

Cat. No.: HY-146067

β-Nor-lapachone is a **Candida glabrata** antibiofilm agent. β-Nor-lapachone can stimulate **ROS** production, inhibits efflux activity, adhesion, biofilm formation and the metabolism of mature biofilms of Candida glabrata. β-Nor-lapachone has antifungal activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg